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Nuclear antigen Ki-67 is widely
accepted as a cell proliferation
marker in both research and can-
cer diagnostic settings. Despite its
extensive use and clinical value,
very little is still known about the
biological function of Ki-67. A
recent work published in Cell
Reports has revealed important
novel aspects of Ki-67 regulation
that could provide new and
extended prognostic and thera-
peutic value.
Ki-67 was first identified in Hodgkin lym-
phoma cell nuclei as an antigen that is
highly expressed in cycling cells but
strongly downregulated in resting G0-
phase cells [1]. Since then, Ki-67 (also
known as MKI67) is known to most of the
scientific community as the prototype
‘cell proliferation marker’. Its translational
value is well established because it is
widely used in the clinic for grading
multiple types of cancers, with important
prognostic value in large cancer cohorts
[2,3]. In diagnostics, biopsies are ana-
lyzed and assigned a percent Ki-67-pos-
itive score; these Ki-67 scores are then
used for prognosis and treatment (e.g.,
to assess potential benefits from chemo-
therapy in breast cancer). Despite its
value in both laboratory and clinical
settings, for several decades little has
been known about the biological function
of Ki-67. Therefore, understanding Ki-67
biology and regulation will provide essen-
tial knowledge that could potentially
benefit the clinical diagnosis and treat-
ment of cancer patients.In the past few years several studies have
revealed interesting aspects of Ki-67 biol-
ogy, and Ki-67 is clearly much more inter-
esting than merely being a marker of cell
proliferation. Studies have uncovered that
Ki-67 is a protein Phosphatase 1 (PP1)-
interacting protein [4], with roles in the
assembly of the perichromosomal layer
on mitotic chromosomes [5]; it is also
important for chromosome dispersal in
mitosis [6], heterochromatin maintenance
[7], and the cell cycle [7].
We spotlight here a recent article that has
unveiled an important aspect of Ki-67
regulation [9] that provides added value
with potential applications in the clinic.
In addition to the absence of this antigen
in cells in G0 phase, the levels and locali-
zation of Ki-67 are regulated according to
the phase of the cell cycle. In interphase
cells, Ki-67 is present in the nucleus,
where it accumulates in the nucleoli in
G2. At the onset of mitosis it relocalizes
to the periphery of the mitotic chromo-
somes (the so-called perichromosomal
layer), where it remains until the G1
nucleus reformation after chromosome
segregation. After this, Ki-67 is reorgan-
ized first in small foci and then coalesces
in the nucleoli (Figure 1). The overall levels
of Ki-76 over the cell cycle are regulated
by different converging mechanisms. One
level of regulation is transcriptional: the
promoter of the gene encoding Ki-67
contains binding sites for the canonical
G1-regulatory E2F family of transcription
factors, leading Ki-67 mRNA levels to
increase in G1 phase [8]. Regulation also
takes place at the protein level: Ki-67
protein is degraded during G1 via the
ubiquitin proteasome complex APC/C–
Cdh1, and this depends on inactivation
of Rb by CDK4/6 [8,10]. These two
opposing mechanisms contribute to the
final balance of this protein across the cell
cycle, and explain the variable levels of the
protein reported in literature.TrendIn a recent study published in Cell Reports
[9], Miller and colleagues used time-lapse
microscopy and single-cell tracking of cell
lines expressing a CDK2 activity sensor to
quantify Ki-67 levels across the cell cycle.
After cell division, the cells either immedi-
ately re-enter the cell cycle and increase
CDK2 activity, or spontaneously turn off
CDK2 and enter temporary quiescence;
cells can then exit the quiescent state and
re-enter the cell cycle by increasing their
CDK2 activity. By tagging endogenous
Ki-67 with a fluorescent protein using
CRISPR-based genome editing, the
authors were able to compare cells that
rapidly re-entered the cell cycle with cells
that had spent different amounts of time in
G0 phase before re-entering the cell
cycle, as well as with cells that remained
in G0 for a prolonged time. From these
analyses the authors discovered that Ki-
67 is uniformly degraded during the G0
and G1 phases, but that its levels increase
again several hours later, concurrently
with the start of S phase. After this point,
Ki-67 levels rise steadily until mitotic exit.
This characteristic seems to be a con-
served trend across different cell lines.
Because Ki-67 levels fall as a function of the
time the cell spends in quiescence, cells
re-entering the cell cycle will have varying
levels of Ki-67 depending on how long they
have been quiescent (Figure 1). After a long
period of quiescence, cells re-entering the
cell cycle have no detectable Ki-67 signal in
G1; this behavior well explains previous
reports on the observed variability of
Ki-67 staining. These observations there-
fore add the important concept that the
level of Ki-67 expression represents a
spectrum that is a function of both cell-
cycle phase and cell history.
With this knowledge, it is now possible to
model Ki-67 protein decay in quiescence
and predict the time elapsed since quies-
cent cells divided – simply by using Ki-67
levels as the readout.s in Biochemical Sciences, Month Year, Vol. xx, No. yy 1
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Figure 1. Ki-67 Gradients during the Cell Cycle. (A) Continuously dividing cells present maximum levels of
Ki-67duringtheG2/M-phase transition, andlevels decrease graduallyas the cell progresses throughthe cell cycle,
being lowest at the G1/S-phase transition. Ki-67 localization also changes over the cell cycle. Images show Ki-67
staining in HeLa cells at different cell-cycle stages (Ki-67 in red, nuclei in blue). (B and C) In quiescence, Ki-67 levels
also decrease gradually, thus when the quiescent cells re-enter the cycle, Ki-67 levels are decreased depending on
the time the cells have spent in quiescence. Accordingly, upon re-entering the cell cycle, a cell that spends a short
time in quiescence (B) will have more Ki-67 than a cell that has spent a long time in G0 (C). The red pattern
represents Ki-67 levels, as shown in the color-scale key. Abbreviation: t, the time a cell spends in quiescence.These findings have major implications for
the clinic, and potentially could improve the
diagnostic power of this already validated
cancer marker. In fact, careful quantifica-
tion of Ki-67 antibody staining can provide
more information than simplywhethera cell
is proliferating or not; it can additionally
distinguish a rapidly cycling cell (with a very
short quiescence stage) from a slowly
cycling cell that spends long periods in
quiescence before re-entering the cell
cycle. The predictive power of this analysis
has been demonstrated by the authors
using four different cell lines (MCF10A,
‘normal’ mammary epithelial cells; A375,2 Trends in Biochemical Sciences, Month Year, Vol. xx, Noskin malignant melanoma; OVCAR3, cis-
platin-refractory ovarian carcinoma; and
MCF7, breast adenocarcinoma) [9]; more-
over, Ki-67 levels appear to be indepen-
dent of the quiescence-inducing stimulus,
possibly indicating that Ki-67 plays a con-
served common role in the cell cycle.
Therefore, Ki-67 levels within a tumor
might indicate how fast the tumor is grow-
ing. Rapidly growing tumors would have a
distribution of Ki-67 levels (in G2-phase
cells) concentrated towards the levels
found in mitotic cells (high). By contrast,
slowly growing G2 tumor cells would have. yyKi-67 levels more similar to the back-
ground Ki-67 levels found in adjacent
non-cancerous tissue. This added classi-
fication could stratify tumors into more
precise categories that can be then used
for better prognostic and treatment
purposes.
It would be of major interest now to join all
these newly discovered biological aspects
together, and identify the essential aspects
that make this proliferation marker such a
powerful prognostic tool and, perhaps in
the future, a clinically relevant target.
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